SEC Form 4 · accession 0001940272-26-000019
TENAX THERAPEUTICS, INC. · TENX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 5:52 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000034956
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F4,F5 | Aug 31, 2026 | P | 403,571 | $1.7905 | A | 5,257,389 | I | See Footnote |
| Common StockF2,F4,F5 | Sep 1, 2026 | P | 179,058 | $1.7959 | A | 5,436,447 | I | See Footnote |
| Common StockF3,F4,F5 | Sep 2, 2026 | P | 187,704 | $1.7985 | A | 5,624,151 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F2The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7700 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F3The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.7750 to $1.8000, inclusive. Each Reporting Person undertakes to provide to Tenax Therapeutics, Inc., any security holder of Tenax Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F4The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
- F5For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.